Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

The erythropoietin-receptor pathway modulates survival of cancer cells

Abstract

Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment. However, the use of erythropoietin to correct cancer anemia and to improve radiation efficacy was disappointing. Erythropoietin-receptor signaling mainly acts via activation of STAT 5, but also crossactivates the antiapoptotic transcription factor NF-κB. This causes neuroprotection against oxidative stress and implies radioprotection. In order to investigate possible radioprotective effects of erythropoietin-receptor signaling, we used an in vitro model system employing HeLa TetOff cells, stably transfected with an expression vector for the erythropoietin-receptor gene. Using electrophoretic mobility shift assays, we could demonstrate strong activation of NF-κB by erythropoietin-receptor signaling in HeLa cells. Activation of NF-κB did not require degradation of IκBα and was not prevented by proteasome inhibition. Furthermore, stimulation with erythropoietin resulted in a 50% increased clonogenicity of erythropoietin-receptor-expressing cells but did not alter radiation sensitivity itself. As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K and Verma A . (2001). Cancer Res., 61, 3561–3565.

  • Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H and Verma A . (2003). Am. J. Pathol., 162, 1789–1806.

  • Albright N . (1987). Radiat. Res., 112, 331–340.

  • Baeuerle PA and Baltimore D . (1996). Cell, 87, 13–20.

  • Batr AS, Perelman N, Luck LR, Shimada H and Malik P . (2003). Lab. Invest., 83, 1477–1487.

  • Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Corica F and Frisina N . (2003). J. Neuropathol. Exp. Neurol., 62, 228–236.

  • Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A and Brines M . (2003). Proc. Natl. Acad. Sci. USA, 100, 4802–4806.

  • Damen JE and Krystal G . (1996). Exp. Hematol., 24, 1455–1459.

  • Digicaylioglu M and Lipton SA . (2001). Nature, 412, 641–647.

  • Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H and Haensgen G . (2003). Int. J. Radiat. Oncol. Biol. Phys., 56, 778–787.

  • Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G and Freund M . (2002). Br. J. Cancer, 87, 1341–1353.

  • Frommhold H, Guttenberger R and Henke M . (1998). Strahlenther. Onkol., 174 (Suppl 4), 31–34.

  • Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E and Einhorn LH . (2001). J. Clin. Oncol., 19, 2875–2882.

  • Harrison LB, Shasha D and Homel P . (2002). Oncology, 63 (Suppl 2), 11–18.

  • Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H . (2003). Lancet, 262, 1255–1260.

  • Hirst DG, Hazlehurst JL and Brown JM . (1984). Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 46, 345–354.

  • Hirst DG and Wood PJ . (1987). Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 51, 597–609.

  • Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA and Peyron JF . (1996). Cell, 86, 787–798.

  • Joiner B, Hirst VK, McKeown SR, McAleer JJ and Hirst DG . (1993). Br. J. Cancer, 68, 720–726.

  • Jung M, Zhang Y, Lee S and Dritschilo A . (1995). Science, 268, 1619–1621.

  • Leyland-Jones B . (2003). Lancet Oncol., 4, 459–460.

  • Littlewood TJ, Bajetta E, Nortier JW, Vercammen E and Rapoport B . (2001). J. Clin. Oncol., 19, 2865–2874.

  • Pajonk F, Pajonk K and McBride WH . (1999). J. Natl. Cancer Inst., 91, 1956–1960.

  • Poskitt TR . (1987). Cancer Invest., 5, 231–236.

  • Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R and Vacca A . (2003). Histopathology, 42, 246–250.

  • Santucci MA, Pierce JH, Zannini S, Fortuna A, Frezza G, Babini L, Rosenstein MM and Greenberger JS . (1994). Stem Cells, 12, 506–513.

  • Suwinski R, Taylor JM and Withers HR . (1999). Radiother. Oncol., 50, 57–66.

  • Verdier F, Chretien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C and Mayeux P . (1998). J. Biol. Chem., 273, 28185–28190.

  • Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J and Friedrich E . (2002). Tumori, 88, 150–159.

Download references

Acknowledgements

This work was funded by the Clotten Foundation, Freiburg, Germany.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frank Pajonk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pajonk, F., Weil, A., Sommer, A. et al. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23, 8987–8991 (2004). https://doi.org/10.1038/sj.onc.1208140

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208140

Keywords

This article is cited by

Search

Quick links